Palatin Technologies (PTN) Q2 2025 earnings summary

Executive summary

• Completed sale of Vyleesi's worldwide rights to Cosette in December 2023, eliminating recurring product revenue and shifting focus to pipeline development and R&D in obesity, ocular, and GI indications.

• Multiple clinical programs advancing, including MC4R agonist obesity assets, bremelanotide/GLP-1 combo, PL9643 for dry eye, and PL8177 for ulcerative colitis, with key data readouts expected in 2025.

• Significant business development activity and partnering interest in ulcerative colitis, diabetic kidney disease, and other non-obesity programs.

• Actively seeking partnerships and additional funding to advance clinical programs and maintain operations.

• Reported progress in obesity, dry eye, ulcerative colitis, and diabetic nephropathy programs, with several at or near key data readouts.

Financial highlights

• No product sales recorded for the quarter or six months ended December 31, 2024, versus $2 million and $4.1 million net product revenue in the prior year periods, due to the Vyleesi sale.

• Net loss for Q2 2025 was $2.4 million, or $(0.12) per share, down from $7.8 million, or $(0.56) per share, in Q2 2024; net loss for the six months was $10.3 million, improved from $13.1 million year-over-year.

• Cash and cash equivalents were $3.4 million as of December 31, 2024, not including $4.3 million raised in February 2025.

• Net cash used in operations was $4.8 million for Q2 2025, improved from $10.5 million in the prior year; $11.9 million used in the six months ended December 31, 2024.

• Gain on sale of Vyleesi totaled $7.8 million for the period.

Outlook and guidance

• Topline data from the Phase 2 obesity study (BMT-801) expected by end of February 2025.

• PL8177 Phase 2 ulcerative colitis data expected in Q1 2025; IND-enabling activities and clinical studies for new obesity programs planned for 2025.

• Management expects existing cash and recent financing to fund operations into the second half of 2025, but substantial doubt exists about ability to continue as a going concern without additional funding.

• May receive up to $159 million in sales-based milestone payments from Cosette for Vyleesi, but none achieved as of December 31, 2024.

• Actively seeking additional funding sources and targeting multiple licensing, collaboration, and spinout deals in 2025.